249 related articles for article (PubMed ID: 27161439)
1. Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.
Thiel C; Cordes H; Conde I; Castell JV; Blank LM; Kuepfer L
Arch Toxicol; 2017 Feb; 91(2):865-883. PubMed ID: 27161439
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.
Lipscomb JC; Haddad S; Poet T; Krishnan K
Adv Exp Med Biol; 2012; 745():76-95. PubMed ID: 22437814
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
Poulin P; Theil FP
J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
[TBL] [Abstract][Full Text] [Related]
4. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
Yoon M; Kedderis GL; Yan GZ; Clewell HJ
Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
[TBL] [Abstract][Full Text] [Related]
5. Quantitative in vitro to in vivo extrapolation of tissues toxicity.
Hamon J; Renner M; Jamei M; Lukas A; Kopp-Schneider A; Bois FY
Toxicol In Vitro; 2015 Dec; 30(1 Pt A):203-16. PubMed ID: 25678044
[TBL] [Abstract][Full Text] [Related]
6. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
Kedderis GL; Lipscomb JC
Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
[TBL] [Abstract][Full Text] [Related]
7. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
8. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.
Yoon M; Campbell JL; Andersen ME; Clewell HJ
Crit Rev Toxicol; 2012 Sep; 42(8):633-52. PubMed ID: 22667820
[TBL] [Abstract][Full Text] [Related]
9. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
10. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
11. In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies.
Klein S; Maggioni S; Bucher J; Mueller D; Niklas J; Shevchenko V; Mauch K; Heinzle E; Noor F
Toxicol Sci; 2016 Jan; 149(1):55-66. PubMed ID: 26420750
[TBL] [Abstract][Full Text] [Related]
12. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
[TBL] [Abstract][Full Text] [Related]
13. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
14. Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen.
Péry AR; Brochot C; Zeman FA; Mombelli E; Desmots S; Pavan M; Fioravanzo E; Zaldívar JM
Toxicol Lett; 2013 Jun; 220(1):26-34. PubMed ID: 23566899
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling for nanoparticle toxicity study.
Li M; Reineke J
Methods Mol Biol; 2012; 926():369-82. PubMed ID: 22975976
[TBL] [Abstract][Full Text] [Related]
16. Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling.
Louisse J; Bosgra S; Blaauboer BJ; Rietjens IM; Verwei M
Arch Toxicol; 2015 Jul; 89(7):1135-48. PubMed ID: 24935252
[TBL] [Abstract][Full Text] [Related]
17. A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles.
Lin Z; Monteiro-Riviere NA; Kannan R; Riviere JE
Nanomedicine (Lond); 2016 Jan; 11(2):107-19. PubMed ID: 26653715
[TBL] [Abstract][Full Text] [Related]
18. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.
Weaver RJ; Betts C; Blomme EAG; Gerets HHJ; Gjervig Jensen K; Hewitt PG; Juhila S; Labbe G; Liguori MJ; Mesens N; Ogese MO; Persson M; Snoeys J; Stevens JL; Walker T; Park BK
Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):767-782. PubMed ID: 28604124
[TBL] [Abstract][Full Text] [Related]
19. A physiologically-based pharmacokinetic model for predicting doxorubicin disposition in multiple tissue levels and quantitative toxicity assessment.
Chao FC; Manaia EB; Ponchel G; Hsieh CM
Biomed Pharmacother; 2023 Dec; 168():115636. PubMed ID: 37826938
[TBL] [Abstract][Full Text] [Related]
20. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity.
Van Summeren A; Renes J; van Delft JH; Kleinjans JC; Mariman EC
Toxicol In Vitro; 2012 Apr; 26(3):373-85. PubMed ID: 22274661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
